Lugano, Switzerland, April 21, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first launch of Adlumiz ® (anamorelin ...
"Cancer-related cachexia and sarcopenia occur in hematologic malignancies, not just gastrointestinal carcinomas and head and neck cancers. Their presence affects all aspects of diagnosis and treatment ...
ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan Lugano, Switzerland, and Osaka, Japan, January 22 ...
Cachexia in older SCLC patients leads to inferior survival rates and increased treatment complications, such as dose reductions and incomplete chemotherapy courses. Patients with cachexia had ...
Cachexia could be the next blockbuster area in cancer therapeutics because of its link to survival outcomes. Physician and researcher Dr. Daniel L Marks discusses the historial challenges to ...
Cachexia causes extreme weight loss and muscle wasting. It is a symptom of various chronic conditions such as cancer, chronic renal failure, HIV, and multiple sclerosis. Cachexia predominantly affects ...
•Cancer cachexia is a highly morbid condition that negatively affects quality of life, reduces tolerance to anticancer therapy, and confers poor survival. Despite this, there is no current US Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results